Affect of vaccination towards extreme COVID-19 within the French inhabitants aged 50 years and above: a retrospective population-based research – BMC Medication

Research design

We performed a retrospective ecological research primarily based on French nationwide surveillance information (see Knowledge sources), from December 28, 2020 (week 53–2020 — begin of the vaccination marketing campaign) to March 6, 2022 (week 9–2022 — finish of Omicron BA.1 wave). The research inhabitants was the French inhabitants aged 50 years and above, stratified into 4 age teams: 50–59, 60–69, 70–79 and 80 years previous and above. We estimated the impression of the primary and second doses of main vaccination and the primary booster, when it comes to the variety of averted hospitalizations (admissions to all sorts of hospitalization providers), ICU admissions and deaths.

Strategies

To compute the variety of averted occasions, we used a technique initially developed for tuberculosis [13], which was later utilized to influenza [14, 15] and extra not too long ago to COVID-19 [6, 7]. Particulars are given in Further file 1: Textual content S1. Mainly, the variety of averted occasions (({N}_{mathrm{averted}})) could be estimated from the variety of noticed occasions (({N}_{mathrm{noticed}})), vaccine protection ((VC)) and vaccine effectiveness ((VE)), as follows:

the place the time period (VCtimes VE) represents the proportion of the inhabitants that’s protected by vaccination. This methodology solely accounts for the direct results of vaccination on extreme outcomes (not its oblique results corresponding to impression on transmission) and due to this fact supplies a decrease certain estimate of the true variety of averted occasions. Moreover, in a situation with out vaccination, it’s possible that extra management measures would have been applied, which we don’t account for right here (i.e. we estimate the impression of vaccination underneath the belief that the identical NPIs would have been applied over the research interval). These two factors might be additional addressed within the dialogue.

This method could be prolonged to account for the week of statement ((w)) and the variety of doses acquired ((ok), starting from one to 3 (two doses and one booster)) [6, 15]:

the place ({VC}_{ok}) represents the vaccine protection of precisely (ok) doses (not not less than (ok) doses).

This method assumes that VE is similar for all vaccinated people, whatever the time elapsed since vaccination. Nevertheless, VE just isn’t fixed over time: it rapidly will increase within the first weeks following vaccination as a result of build-up of immunity and declines over time attributable to waning immunity [16,17,18,19]. To be able to account for the evolution of VE in line with the time elapsed since vaccination (left(Delta proper)) in weeks, we modified the method as follows:

the place ({VE}_{ok, Delta }) is the vaccine effectiveness of the (ok)^th dose (Delta) weeks after vaccination, and ({VP}_{w,ok,Delta }) represents the proportion of people that acquired their final dose (ok) precisely (Delta) weeks earlier than the week of statement (w). Of be aware, the sum of ({VP}_{w,ok,Delta }) over all (Delta) corresponds to the vaccine protection of precisely (ok) doses on week (w) ((sum_{Delta =0}^{w-1}{VP}_{w,ok,Delta }={VC}_{w,ok})).

This method was utilized individually for every age group and every variant, with a purpose to account for various VE in line with age teams and variants. The entire variety of occasions immediately averted by vaccination (variety of hospitalizations, ICU admissions and deaths) was then obtained by summing the variety of averted occasions over all weeks, age teams and variants. All analyses have been performed in R software program model 4.1.2 (R Basis, Vienna, Austria).

Knowledge sources

For the variety of noticed occasions, we relied on hospitalization and dying information from the SI-VIC database, maintained by the ANS (Agence du Numérique en Santé) and despatched every day to Santé publique France, the French nationwide public well being company. This database supplies real-time information on sufferers hospitalized for COVID-19 in French private and non-private hospitals, together with their age, date of hospitalization, sort of hospitalization providers and end result (discharged/deceased). All COVID-19 instances are both biologically confirmed or current with a computed tomographic picture extremely suggestive of SARS-CoV-2 an infection. For hospitalizations, we included sufferers hospitalized in all sorts of providers (normal wards, ICU, long-term care and rehabilitation, emergency care…) and excluded sufferers hospitalized for causes not linked to a COVID-19 an infection. For deaths, we included all sufferers deceased within the hospitals with a COVID-19 an infection and added people deceased in nursing properties (resident properties for aged) with a COVID-19 an infection from the SurvESMS database. The SurvESMS database, administered by Santé publique France, was designed for the monitoring of COVID-19 instances and deaths among the many residents of nursing properties; it permits the excellence between residents who died in nursing properties from those that died in hospitals (already accounted for within the SI-VIC database). Within the absence of knowledge on age, people have been thought of 80 + years previous; this assumption was primarily based on 2019 information which confirmed that the imply age of individuals deceased in nursing properties was 89 years previous [20]. Deaths at house couldn’t be accounted for. The time sequence of hospitalizations, ICU admissions and deaths in line with every variant have been reconstructed utilizing the SI-DEP database, the nationwide surveillance system describing SARS-CoV-2 RT-PCR and antigen take a look at outcomes arising from all personal and public French laboratories (see particulars in Further file 1: Textual content S2). The three databases (SI-VIC, SurvESMS and SI-DEP) are meant to be exhaustive.

Concerning vaccine protection, we used the VAC-SI database, the nationwide data system developed by the French Well being Insurance coverage to observe the implementation of COVID-19 vaccination campaigns, for the reason that begin of vaccine distribution in December 2020, throughout the nation. Particular person information embrace the variety of doses, the date of vaccination, the kind of vaccine, and socio-demographic data corresponding to age. All sorts of vaccine have been thought of (Pfizer/BioNTech BNT162b2, Moderna mRNA-1273, Oxford/AstraZeneca ChAdOx1-S and Johnson & Johnson Ad26.COV2.S). For every week of statement (w) and every age group, the variety of vaccinated people in line with the variety of doses acquired earlier than the week of statement (w) and to the week of vaccination (with a purpose to compute the time elapsed since vaccination, (Delta)) have been extracted. For every particular person, on a given week of statement (w), solely the final dose acquired earlier than that week was taken into consideration, to keep away from counting the identical individual twice: e.g. when a person acquired a second dose on week (w), they have been not counted among the many first-dose people from week (w) onwards (they have been solely counted among the many first-dose people as much as week (w-1)). We excluded people for which the date of the primary dose was posterior to the date of the second dose or the booster dose, or the date of the second dose was posterior to the date of the booster. For the denominator (variety of people per age group within the French inhabitants), we used 2022 demographic information from the Nationwide Institute of Statistics and Financial Research (INSEE).

On the subject of the effectiveness of COVID-19 vaccines towards COVID-19 variants, we extracted information from a current VE research performed by Santé publique France [12]. The research investigated VE of the 2 mRNA vaccines Pfizer/BioNTech BNT162b2 and Moderna mRNA-1273 towards Alpha (unpublished information), Delta and Omicron BA.1 extreme outcomes (normal ward hospitalizations and ICU/deaths) amongst immunocompetents ≥ 50 years previous French people, between January 11, 2021, and February 10, 2022. Analyses have been carried out in line with 50–79 and 80 years previous and above age teams, and the variety of vaccine doses (one dose, two doses and the primary booster dose). VE in line with time since vaccination have been additionally estimated. These estimates have been smoothed to take away random fluctuations over time.

Word that VE towards Omicron extreme outcomes have been sourced from a number of research obtainable within the literature: the aforementioned French research for VE of the primary dose towards ICU/deaths [12], a test-negative case–management research in England for VE towards hospitalizations amongst folks aged 65 years and older (which we utilized to our 50 + inhabitants) [21], and a test-negative case–management research in Canada for VE of the second dose and booster towards deaths amongst folks aged 18 years and older (which we utilized to our 50 + inhabitants) [16].

In these three research, the date related to a person is the date of the take a look at or the date of symptom onset. To be able to account for the time between the take a look at or symptom onset and the occasion of curiosity (hospitalization, ICU admission or dying), we utilized a lag of 1 week to VE towards hospitalization and ICU admission and a lag of two weeks to VE towards dying. Lastly, a linear decay of VE was assumed to account for the waning of immunity at longer time horizons. The decay values have been extracted from the literature and set to − 0.5 factors/week for the second dose after 21 weeks [22, 23] and − 0.4 factors/week for the booster dose after 21 weeks [24]. Within the absence of knowledge from the literature for the primary dose, we utilized a coefficient twice greater than for the second dose (− 1 level/week). This coefficient was utilized from the thirteenth week after vaccination [25]. To be able to estimate uncertainty across the variety of averted occasions, we used the 95% confidence intervals of VE estimates revealed within the three aforementioned research [12, 16, 21].